BioSpectrum Asia - October 2019
Get BioSpectrum Asia along with 7,500+ other magazines & newspapers
Try FREE for 7 days
Latest and past issues of 7,500+ magazines & newspapers
Digital Access. Cancel Anytime.
Share with 4 family members.1 Year$99.99
Latest and past issues of 7,500+ magazines & newspapersDigital Access. Cancel Anytime.Share with 4 family members.Get BioSpectrum Asia
1 Year $10.99
Save 7%12 issues starting from BioSpectrum Asia July 2022 Digital Access. Cancel Anytime.Buy this issue $0.99
October 2019 issue Digital Access. - Magazine Details
- In this issue
Magazine Description
In this issue
Improved regulatory support push Clinical Research in Asia The prevalence of infectious and tropical diseases is creating an unmet clinical needs in emerging countries. Owing to these, a large number of the population participate in clinical trials to access high-quality healthcare free of cost. India and China have the highest prevalence rates for metabolic disorders, due to the increasing population, combined with the prevalence of insulin resistance, hyperlipidemia, and obesity. Besides the Asian region has the potential for large patient recruitment, cost reduction, the improved regulatory environment making it a favourable destination for clinical trials.
Cancel Anytime [ No Commitments ]
Digital Only
India Unveils Angel Investor Network For Biotech Startups
To unlock the potential of Indian the Biotechnology startups, Industry Research Assistance Council (BIRAC) has collaborated with the Indian Angel Network (IAN) to launch an angel investor network, BioAngels.
80% Of Premature Heart Attacks And Strokes Are Preventable
Widespread chronic disease and ageing populations are necessitating a pressing change in the model of care, as there will be close to half a billion people aged 65 and older in the Asia Pacific (APAC) region by 2025.
AIM brings innovations from labs to hospitals and masses
The human body, like Space, is an endless frontier made even more complex by the irreversibility of life by the arrow of time. Similar to the mystery of origin of the Universe some problems in the human body are so complex, for example, the problem of qualia or the hard problem of consciousness– ‘Why any physical state is conscious rather than nonconscious’ that it has given the league of neuroscientists, philosophers and empiricists a perpetual “Whereof one cannot speak, thereof one must be silent” or the Upanishadic ‘Neti Neti’ limbo.
It is our goal to fuel R&D in the region
UK-based Abcam, a global innovator working together with life scientists to advance research and enable faster breakthroughs, has officially opened its newest regional hub in Singapore recently.
Ensuring Digital Health Standards
The use of digital health (DH) has grown rapidly over the last couple of years - accelerating even more during the COVID-19 pandemic. As DH becomes part of the traditional healthcare system, it's important to have stringent regulations and higher levels of scrutiny. Regulators around the world and in Asia are realising this fact and changing regulations accordingly. Let's look at the regulatory landscape in APAC.
Targeting Optimal DRUG DELIVERY
In recent years, several innovations have emerged around long-acting formulations and medical device development to improve patient compliance. Consequently, the growing need for controlled drug release coupled with technological advancements in pharmacology is promoting the adoption of novel drug delivery systems (NDDS). It is now crucial for Asia Pacific (APAC) drug formulators to learn and act upon these advances in therapeutic modalities that address long-standing bioavailability, dosage, and ingestion challenges of drug components to remain competitive in the global market. Simultaneously, it's essential to optimise the therapeutic efficacy and safety profiles of a drug by regulating dosage parameters, while DDS plays an important role in administering drugs, vaccines, and therapeutic agents. Optimising these techniques enhance the performance efficacy ratio of medications by economically managing therapeutics assets. Let's examine recent advancements in drug delivery modalities that are greatly encouraging stakeholders' collaboration among innovators, manufacturers, investors, and contract development and manufacturing companies (CDMOs) who are capitalising on competitive advantages.
China, Brazil join hands to boost health cooperation
Ma Xiaowei, Minister of China’s National Health Commission (NHC) recently had a meeting with Marcelo Queiroga, Brazil’s Health Minister to exchange views on further deepening bilateral and multilateral health cooperation.
India develops tiny robots to enhance dental care
Nano-sized robots manipulated using a magnetic field can help kill bacteria deep inside dentinal tubules, and boost the success of root canal treatments, as per a new study by researchers at the Indian Institute of Science (IISc) and IIScincubated startup, Theranautilus.
Our approach to managing the side effects of cancer therapy has evolved
Although there has been tremendous progress in discovering and developing new therapies to treat cancer patients, innovation in treating or preventing the side effects has lagged in comparison.
WHO validates China's Convidecia as 11th vaccine for COVID-19
The World Health Organisation (WHO) has issued an emergency use listing (EUL) for Convidecia, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19 caused by SARS-CoV-2.
